296 related articles for article (PubMed ID: 23847759)
41. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic Hematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukemia: Shifting Indications in the Era of Immunotherapy.
Truong TH; Jinca C; Mann G; Arghirescu S; Buechner J; Merli P; Whitlock JA
Front Pediatr; 2021; 9():782785. PubMed ID: 35004545
[TBL] [Abstract][Full Text] [Related]
43. Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs.
Bustamante-Ogando JC; Hernández-López A; Galván-Díaz C; Rivera-Luna R; Fuentes-Bustos HE; Meneses-Acosta A; Olaya-Vargas A
Front Oncol; 2023; 13():1304805. PubMed ID: 38304036
[TBL] [Abstract][Full Text] [Related]
44. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults.
Lee KJ; Chow V; Weissman A; Tulpule S; Aldoss I; Akhtari M
Ther Clin Risk Manag; 2016; 12():1301-10. PubMed ID: 27601914
[TBL] [Abstract][Full Text] [Related]
45. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Lulla PD; Mamonkin M; Brenner MK
Cancer J; 2019; 25(3):199-207. PubMed ID: 31135527
[TBL] [Abstract][Full Text] [Related]
46. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
47. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
48. Harnessing immunotherapy for pediatric T-cell malignancies.
Diorio C; Teachey DT
Expert Rev Clin Immunol; 2020 Apr; 16(4):361-371. PubMed ID: 32103690
[TBL] [Abstract][Full Text] [Related]
49. Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation.
Boatsman EE; Fu CH; Song SX; Moore TB
J Pediatr Hematol Oncol; 2010 Mar; 32(2):e57-60. PubMed ID: 20168246
[TBL] [Abstract][Full Text] [Related]
50. [Recent advances and future directions in CAR-T cell therapy in pediatric oncology].
Ceppi F; Renella R; Diezi M; Ansari M; Duchosal MA; Arber C; Kandalaft L; Coukos G; Beck-Popovic M
Rev Med Suisse; 2019 Jan; 15(N° 632-633):85-91. PubMed ID: 30629377
[TBL] [Abstract][Full Text] [Related]
51. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
52. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
[TBL] [Abstract][Full Text] [Related]
53. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
54. Role of chemokines in T-cell acute lymphoblastic Leukemia: From pathogenesis to therapeutic options.
Zhao Y; Guo R; Cao X; Zhang Y; Sun R; Lu W; Zhao M
Int Immunopharmacol; 2023 Aug; 121():110396. PubMed ID: 37295031
[TBL] [Abstract][Full Text] [Related]
55. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
56. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
57. Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.
McLaughlin L; Cruz CR; Bollard CM
Ther Adv Hematol; 2015 Dec; 6(6):295-307. PubMed ID: 26622998
[TBL] [Abstract][Full Text] [Related]
58. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
59. [CAR-T therapy for pediatric acute lymphoblastic leukemia].
Sakaguchi H
Rinsho Ketsueki; 2023; 64(11):1440-1446. PubMed ID: 38072432
[TBL] [Abstract][Full Text] [Related]
60. Novel therapies for pediatric acute lymphoblastic leukemia.
Graff Z; Burke MJ; Gossai N
Curr Opin Pediatr; 2024 Feb; 36(1):64-70. PubMed ID: 37991046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
